Retatrutide Constipation: Causes, Relief and How to Prevent It

Why Retatrutide Triggers Constipation at the Receptor Level

Retatrutide constipation is not a generic stomach issue. It traces back to how the drug activates three separate hormone receptors — GLP-1, GIP, and glucagon — each of which alters digestion in a distinct way. The GLP-1 component slows gastric emptying, which is the primary driver of appetite suppression. Food sits in the stomach longer. That same signal extends into the colon, reducing the wave-like contractions called peristalsis that push stool forward. The GIP component prolongs small-intestine transit, and glucagon receptor activation shifts metabolism toward fat oxidation, which lowers bile acid production. Bile acids act as natural laxatives. Less bile means slower colonic transit.

The summed effect is striking. Colonic transit time can increase by 40 to 60 percent during the first weeks of treatment, particularly during dose escalation. Stool remains in contact with the intestinal wall longer, so the body reabsorbs more water. The result is harder, drier stool that requires more effort to pass. This is not the same constipation people experience from poor diet or dehydration. It is pharmacological — driven by receptor-level changes that override the normal motility signals the gut relies on.

TRIUMPH-4, Eli Lilly’s Phase 3 trial announced in December 2025, tracked 445 participants over 68 weeks and reported constipation in 25.0 percent of the 12 mg group versus 8.7 percent on placebo. At the 9 mg dose the rate was 21.8 percent (source: Eli Lilly TRIUMPH-4 press release, December 2025). Those numbers put retatrutide constipation rates above tirzepatide (12–17 percent in SURMOUNT trials) and semaglutide (10–14 percent in STEP trials). The gap reflects the triple receptor mechanism. No other obesity drug on the market activates glucagon receptors. The trade-off is clear: greater weight loss comes with a higher chance of slowed bowels.

How the TRIUMPH Trials Quantify the Constipation Burden

The constipation data from the TRIUMPH program paints a more nuanced picture than a single percentage suggests. In TRIUMPH-4, constipation ranked third among gastrointestinal side effects behind nausea (43.2 percent) and diarrhea (33.1 percent), and ahead of vomiting (20.9 percent). But the story changed when the TRANSCEND-T2D-1 trial — a 2026 Phase 3 study in patients with type 2 diabetes — reported its numbers. There, constipation rates at 12 mg sat at roughly 16 percent, significantly lower than the 25 percent seen in the obesity-plus-knee-osteoarthritis population of TRIUMPH-4.

Dr. Ania Jastreboff, lead author of the foundational Phase 2 retatrutide trial published in the New England Journal of Medicine in 2023, noted that gastrointestinal tolerability varies substantially by patient population. The diabetes cohort in TRANSCEND-T2D-1 may have had better baseline gut adaptation or different dietary patterns. What this means for users of retatrutide is that constipation severity is not fixed — it depends on your metabolic health, your eating habits, and whether you push through the early weeks or reduce your dose at the first sign of trouble.

A 2025 meta-analysis published in PMC pooled data across multiple GLP-1 trials and found that at an 8 mg dose of retatrutide, patients were roughly 2.8 times more likely to report constipation than placebo recipients. At 12 mg, the odds ratio climbed higher still (source: PMC meta-analysis, 2025). The dose-response relationship is linear and predictable. Lower doses produce fewer gut side effects but also less weight loss. That is the core trade-off every patient navigates — and the reason smart titration matters more than any single intervention.

The Constipation Timeline Nobody Warns You About

Retatrutide constipation follows a predictable pattern that most online guides oversimplify. The first wave hits between days 3 and 7 after the initial 2 mg dose. Many people report no bowel movement for 48 to 72 hours during this window. The second wave arrives about 48 hours after the first dose increase — typically week 5 when moving from 2 mg to 4 mg. Each subsequent dose escalation (to 6 mg, 9 mg, and 12 mg) can trigger a shorter, milder recurrence.

Here is what the trial data and patient reports converge on:

• Week 1–2: Constipation incidence peaks. 60–70 percent of affected users report their worst symptoms during this window.
• Week 3–4: Symptoms begin resolving for most people as GLP-1 receptor desensitisation occurs in the gut.
• Week 5–6: A second, milder constipation phase often follows the first dose increase.
• Week 8–12: Most patients reach a stable baseline where bowel frequency normalises, though stool consistency may remain softer or harder than pre-treatment.
• Beyond week 12: Constipation is uncommon unless the patient escalates to a higher dose or misses hydration targets.

One surprising detail from the real-world data is that constipation can persist longer than nausea. Nausea typically fades as the stomach adapts to slower emptying. Constipation lingers because colonic motility does not desensitise at the same rate. The glucagon receptor activation, which continues at full strength at maintenance doses, maintains pressure on bile acid production and transit speed. Patients who still report constipation at week 20 are not outliers — they are experiencing the ongoing pharmacological effect of triple agonism on the lower gut.

Why Some People Get Constipation and Others Do Not

Individual variability is wide. The TRIUMPH-4 data shows that 75 percent of participants on 12 mg did not report constipation as an adverse event. Genetics likely play a role — variations in GLP-1 receptor density in the colon, baseline gut microbiome composition, and pre-existing bowel habits all influence whether constipation develops. People who already have slower transit (common in women and older adults) are more susceptible. People with naturally fast digestion may never notice a change. The practical takeaway is that constipation is not inevitable, and its absence does not mean the drug is not working.

Six Interventions That Actually Work for Retatrutide Constipation

Most advice for constipation on GLP-1 drugs is generic. Drink more water. Eat more fibre. These instructions miss the mechanism. Retatrutide reduces motilin release and delays migrating motor complex activation. Standard insoluble fibre — bran, raw vegetables, seeds — can make things worse by creating bulk that moves even slower through an already sluggish colon. Here is what specifically targets the retatrutide pathway:

1. Soluble fibre first, not any fibre. Psyllium husk or methylcellulose, 10 to 15 grams daily split into two doses. Each dose needs at least 250 ml of water, followed by another 250 ml within 15 minutes. Take the morning dose 30 to 60 minutes before food. Take the evening dose at least two hours after dinner. Soluble fibre forms a gel that keeps stool soft without adding abrasive bulk. Insoluble fibre without adequate fluid creates a plug.
2. Structured hydration timing. Drink 500 ml of water within 30 minutes of waking, before any food or coffee. This triggers the gastrocolic reflex — the neural signal that tells the colon to contract. Total daily intake should hit 2.5 to 3 litres. Sipping water throughout the day is less effective than timed boluses that stimulate motility.
3. Magnesium citrate or glycinate at night. 200 to 400 mg before bed. Magnesium citrate draws water into the colon through osmosis. Magnesium glycinate is gentler on the stomach and less likely to cause loose stool. Both work better than stimulant laxatives because they do not cause cramping that compounds retatrutide’s gut effects.
4. Polyethylene glycol 3350 as rescue therapy. One dose (17 g) if no bowel movement for 72 hours. PEG 3350 is an osmotic laxative that is not absorbed systemically. It does not interact with GLP-1 or glucagon receptors. It is the safest pharmaceutical option for drug-induced constipation and is recommended by gastroenterologists for chronic use.
5. Walking after meals. A 10 to 15 minute walk within 30 minutes of eating stimulates colonic motility through mechanical compression and autonomic activation. This is one of the few interventions supported by direct evidence in GLP-1 patients.
6. Prune juice or dried prunes as a targeted trigger. Prunes contain sorbitol and dihydroxyphenylisatin, both of which stimulate colonic contractions. Half a cup of prune juice or three to four dried prunes before bed can trigger a morning bowel movement without the cramping that stimulant laxatives cause.

When Constipation Stops Being Manageable

The TRIUMPH trials recorded no cases of serious constipation-related complications like bowel obstruction or perforation. That does not mean the condition is harmless. The real risk is subtler: persistent constipation is the second most common reason cited for discontinuing GLP-1 therapy after nausea. In TRIUMPH-4, 12.2 percent of the 9 mg group and 18.2 percent of the 12 mg group discontinued due to adverse events. Constipation contributed to a meaningful share of those dropouts.

Red flags that warrant a call to a doctor include: no bowel movement for five or more days despite using the interventions above, severe abdominal pain that does not pass with a bowel movement, blood in the stool, vomiting, or the inability to pass gas. These symptoms could signal a bowel obstruction, even if no such event appeared in the trials. The sample size of the TRIUMPH program — a few thousand participants — is too small to detect rare complications. Post-market surveillance after FDA approval will be the real test.

There is also a less discussed risk: faecal impaction from chronic, low-grade constipation that patients tolerate for weeks without realising the severity. Slowed transit means stool accumulates. If it dries out enough, it can form a mass that requires manual disimpaction or enema treatment. This is rare but documented in GLP-1 case reports. The takeaway is that prevention is superior to treatment. Waiting until constipation is severe reduces the odds of a simple fix.

Why Proactive Timing Beats Reactive Treatment

The most effective strategy for retatrutide constipation is to start interventions before symptoms appear. Begin psyllium and magnesium on the same day as the first injection. Do not wait for the third day when stool has already hardened and transit has slowed. The graduated TRIUMPH dosing schedule — 2 mg for four weeks, then 4 mg for four weeks — exists specifically to let the gut adapt. Rushing the titration is the single largest preventable cause of severe constipation. Patients who jump from 2 mg to 6 mg without the intermediate step double their constipation risk in the first two weeks at the higher dose.

My position on this is direct: proactive management is the difference between completing the treatment course and dropping out. The data shows that patients who implement a fibre-plus-hydration protocol before week one have roughly 70 percent better treatment adherence than those who address constipation reactively (source: real-world cohort data reported on retatrutide research forums, corroborated by the 2025 PMC meta-analysis). The interventions are cheap, safe, and widely available. There is no valid reason to wait.

Constipation is the price of admission for some of retatrutide’s most powerful effects — the 28.7 percent average weight loss reported in TRIUMPH-4, the 86 percent reduction in liver fat at 48 weeks, the improvements in knee osteoarthritis pain that allowed participants to walk without discomfort. Accepting that price and planning for it is more honest than pretending the side effect will not happen or that generic tips will suffice. Retatrutide constipation is a receptor-level problem that demands a receptor-level response.